ATG16L1 and neoplasm: Previous research analyzed the relationship between genetic variants of the autophagy pathway and clinical outcomes in 458 prostate cancer patients, which indicated that high expression of ATG16L1 was correlated with lower tumor aggressiveness and favorable prognosis [17].